XFRA NEW INSTRUMENTS AVAILABLE ON 17.06.2025

The following instruments on XETRA do have their first trading 17.06.2025
Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 17.06.2025

Aktien

1 CA65346B1013 Nexcel Metals Corp.
2 US31572Q8814 FibroGen Inc.
3 US34986A1043 Forward Air Corp.
4 US75382E2081 Rapt Therapeutics Inc.
5 US81728A2078 Sensei Biotherapeutics Inc.

Anleihen/ETF

1 ES0201001197 Ayuntamiento de Madrid
2 BE0390226927 bpost S.A.
3 FR0014010JY4 SFIL S.A.
4 XS3086867440 ELM B.V.
5 XS3091679962 Selecta Group B.V.
6 XS3095384809 SSE PLC
7 NO0013515759 BOS GmbH & Co. KG
8 XS3099011853 Equitable Bank
9 US29786AAP12 Etsy Inc.
10 US337932AU11 FirstEnergy Corp.
11 US337932AS64 FirstEnergy Corp.
12 XS3091296288 FMO
13 US91282CNH06 United States of America
14 FR0014010IV2 Orange S.A.
15 XS3095397454 SSE PLC
16 DE000DJ9AV61 DZ BANK AG
17 IE0008JXFQK8 HSBC PLUS USA Equity Quant Active UCITS ETF
18 IE000ZURGSV2 HSBC PLUS World Equity Quant Active UCITS ETF
19 IE000KL4O2Z8 HSBC PLUS World Equity Income Quant Active UCITS ETF
20 LU1852211645 UBS Sustainable Development Bank Bonds UCITS ETF

Vorsicht, geheim!

2026 startet mit einem Paukenschlag: Der DAX outperformt den US-Markt, Nachzügler holen auf. Ein erstes Signal, dass der Bullenmarkt an Breite gewinnt. Während viele Anleger weiter auf die großen Tech-Namen setzen, hat sich im Hintergrund längst ein Umschwung vollzogen. Der Fokus verschiebt sich weg von überteuerten KI-Highflyern hin zu soliden Qualitätswerten aus der zweiten Reihe.

Anleger, die jetzt clever agieren, setzen nicht auf das, was war, sondern auf das, was kommt. Unternehmen mit gesunder Bilanz, unterschätztem Potenzial und begrenztem Abwärtsrisiko könnten 2026 zu den großen Gewinnern zählen. Die Gefahr einer schärferen Korrektur bleibt real, gerade für passiv aufgestellte Investoren.

In unserem neuen Spezialreport stellen wir fünf Aktien vor, die genau jetzt das Potenzial für überdurchschnittliche Renditen bieten. Stark, günstig und bislang kaum im Fokus.

Jetzt kostenlosen Report herunterladen – bevor es andere tun!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.

Hier klicken

Zeit	Aktuelle Nachrichten
21.01.	Stifel raises Forward Air stock price target to $32 on asset-light LTL model
06.11.25	Forward Air: Jefferies senkt Kursziel wegen Marktvolatilität auf 30 US-Dollar
06.11.25	Forward Air stock price target lowered to $30 by Jefferies on market volatility
06.11.25	Forward Air says strategic review, potential sale still on track
06.11.25	Forward Air outlines ongoing strategic review and cost initiatives as consolidated EBITDA reaches $78M in Q3 2025

Zeit

Aktuelle Nachrichten

21.01.

Stifel raises Forward Air stock price target to $32 on asset-light LTL model

06.11.25

Forward Air: Jefferies senkt Kursziel wegen Marktvolatilität auf 30 US-Dollar

06.11.25

Forward Air stock price target lowered to $30 by Jefferies on market volatility

06.11.25

Forward Air says strategic review, potential sale still on track

06.11.25

Forward Air outlines ongoing strategic review and cost initiatives as consolidated EBITDA reaches $78M in Q3 2025

Zeit	Aktuelle Nachrichten
07.01.	FIBROGEN INC - 8-K, Current Report
07.01.	FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB
07.01.	FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum	Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq... ► Artikel lesen
15.12.25	FibroGen: FDA Grants Orphan Drug Designation To Roxadustat For MDS
15.12.25	FibroGen, Inc.: Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration	Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan... ► Artikel lesen

Zeit

Aktuelle Nachrichten

07.01.

FIBROGEN INC - 8-K, Current Report

07.01.

FibroGen rebrands as Kyntra Bio with new Nasdaq ticker KYNB

07.01.

FibroGen, Inc.: FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

Name change to Kyntra Bio reflects the newly sharpened focus of the Company on novel therapies with potential for outsized impact in oncology and rare diseaseKyntra Bio will begin trading on Nasdaq...
► Artikel lesen

15.12.25

FibroGen: FDA Grants Orphan Drug Designation To Roxadustat For MDS

15.12.25

FibroGen, Inc.: Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration

Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan...
► Artikel lesen

Zeit	Aktuelle Nachrichten
Fr	Nexcel Metals Corp: Nexcel Metals amends Burnt Hill property agreement
Do	Nexcel Metals Corp.: Nexcel Amends Agreement for the Acquisition of an Additional 42% Interest in the Burnt Hill Tungsten Project	Vancouver, British Columbia--(Newsfile Corp. - February 5, 2026) - Nexcel Metals Corp. (CSE: NEXX) (OTCQB: NXXCF) (FSE: 2OH) ("Nexcel" or the "Company") is pleased to announce that, further to its... ► Artikel lesen
Di	Nexcel ignites Burnt Hill tungsten deal: Nexcel Metals (CSE:NEXX) has entered into a purchase agreement to acquire ...
02.02.	Nexcel Metals Corp.: Nexcel Announces the Acquisition of an Additional 42% Interest in the Burnt Hill Tungsten Project	Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - Nexcel Metals Corp. (CSE: NEXX) (OTCQB: NXXCF) (FSE: 2OH) ("Nexcel" or the "Company") is pleased to announce that it has entered... ► Artikel lesen
06.01.	Nexcel Metals Corp: Nexcel Metals files short form prospectus

Zeit

Aktuelle Nachrichten

Nexcel Metals Corp: Nexcel Metals amends Burnt Hill property agreement

Nexcel Metals Corp.: Nexcel Amends Agreement for the Acquisition of an Additional 42% Interest in the Burnt Hill Tungsten Project

Vancouver, British Columbia--(Newsfile Corp. - February 5, 2026) - Nexcel Metals Corp. (CSE: NEXX) (OTCQB: NXXCF) (FSE: 2OH) ("Nexcel" or the "Company") is pleased to announce that, further to its...
► Artikel lesen

Nexcel ignites Burnt Hill tungsten deal: Nexcel Metals (CSE:NEXX) has entered into a purchase agreement to acquire ...

02.02.

Nexcel Metals Corp.: Nexcel Announces the Acquisition of an Additional 42% Interest in the Burnt Hill Tungsten Project

Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - Nexcel Metals Corp. (CSE: NEXX) (OTCQB: NXXCF) (FSE: 2OH) ("Nexcel" or the "Company") is pleased to announce that it has entered...
► Artikel lesen

06.01.

Nexcel Metals Corp: Nexcel Metals files short form prospectus

Zeit	Aktuelle Nachrichten
23.01.	Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals	LONDON (dpa-AFX) - This week's biotech landscape was shaped by workforce restructuring, high-profile acquisitions, and clinical trial data readouts across key therapeutic areas such as ovarian... ► Artikel lesen
22.01.	GSK To Acquire RAPT Therapeutics In $2.2 Billion Deal, Adding Long-Acting Anti-IgE Food Allergy Program
21.01.	GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout
21.01.	IN BRIEF: RTW Biotech welcomes GSK deal to buy RAPT Therapeutics
21.01.	Nach 2,2-Milliarden-Dollar-Übernahme durch GSK: Leerink Partners stuft Rapt Therapeutics herab

Zeit

Aktuelle Nachrichten

23.01.

Weekly Buzz: IOBT Slashes Jobs; GSK To Acquire RAPT; CORT's Ovarian Cancer Study Meets Goals

LONDON (dpa-AFX) - This week's biotech landscape was shaped by workforce restructuring, high-profile acquisitions, and clinical trial data readouts across key therapeutic areas such as ovarian...
► Artikel lesen

22.01.

GSK To Acquire RAPT Therapeutics In $2.2 Billion Deal, Adding Long-Acting Anti-IgE Food Allergy Program

21.01.

GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout

21.01.

IN BRIEF: RTW Biotech welcomes GSK deal to buy RAPT Therapeutics

21.01.

Nach 2,2-Milliarden-Dollar-Übernahme durch GSK: Leerink Partners stuft Rapt Therapeutics herab

Zeit	Aktuelle Nachrichten
23.12.25	Sensei Biotherapeutics, Inc. - 8-K, Current Report
05.12.25	What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After-Hours Jump?
05.12.25	Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed	WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen
14.11.25	Sensei shrinks workforce by 65%, terminates 3 executive roles
14.11.25	Sensei BioTherapeutics GAAP EPS of -$3.62

Zeit

Aktuelle Nachrichten

23.12.25

Sensei Biotherapeutics, Inc. - 8-K, Current Report

05.12.25

What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After-Hours Jump?

05.12.25

Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed

WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei...
► Artikel lesen

14.11.25

Sensei shrinks workforce by 65%, terminates 3 executive roles

14.11.25

Sensei BioTherapeutics GAAP EPS of -$3.62

Unternehmen / Aktien	Kurs	%
FORWARD AIR CORPORATION	23,400	0,00 %
KYNTRA BIO INC	6,850	-2,84 %
NEXCEL METALS CORP	0,350	-48,53 %
RAPT THERAPEUTICS INC	47,600	-0,83 %
SENSEI BIOTHERAPEUTICS INC	8,770	-1,02 %

Unternehmen / Aktien

Kurs

FORWARD AIR CORPORATION

23,400

0,00 %

KYNTRA BIO INC

6,850

-2,84 %

NEXCEL METALS CORP

0,350

-48,53 %

RAPT THERAPEUTICS INC